Appointment of Internal Auditors for the FY 2026-27
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Akums Drugs and Pharmaceuticals reported its Q4 and full year FY2026 audited financial results. Standalone net profit for FY2026 was Rs. 1,116.40 million compared to Rs. 1,609.98 million in FY2025, reflecting a decline. The Board recommended a final dividend of Rs. 1 per share and a special dividend of Rs. 2 per share (total Rs. 3 per share), subject to shareholder approval at the 22nd AGM scheduled for July 10, 2026. The company appointed Mahajan & Aibara LLP as Internal Auditors for FY2026-27. Additionally, there was a change in Senior Management Personnel with Mr. V. Jagannathan appointed as President-HR and Mr. Arvind Srivastava ceasing to be Senior Management Personnel. The auditors highlighted an ongoing Income Tax Department search and seizure operation from January 2025 and subsequent show cause notices as an emphasis of matter.
The decline in annual profits may create short-term negative sentiment, though the special dividend announcement could provide some support to the stock price. The HR leadership change represents a routine management transition that investors will monitor.